Abstract | BACKGROUND: METHODS: GFAP IgG was detected by indirect immunofluorescence assay. The patient's data were analyzed retrospectively. RESULTS: A 48-year-old man presented with anxiety, depression, cognitive decline, tremor, gait disturbance, and fecal and urine incontinence. Autoimmune GFAP-A was diagnosed based on the following: (1) T2-weighted and fluid-attenuated inversion recovery MRI findings of hypersensitive lesions in the subcortical and deep white matter of the brain, with multiple longitudinally extensive lesions in the cervical and chest regions of the spinal cord, and (2) high levels of GFAP IgG in the CSF. Clinical symptoms and abnormalities detected on neuroimaging worsened after administration of high-dose intravenous methylprednisolone (IVMP) and intravenous immunoglobulin ( IVIG) but improved significantly after PAIA therapy. CONCLUSION: Psychological impairment can be the first sign of autoimmune GFAP-A. PAIA might be an effective treatment for patients with GFAP-A who respond poorly to conventional IVMP and IVIG therapy.
|
Authors | Bing Qin, Ruizhen Wu, Yaqing Shu, Yuge Wang, Boguang Yu, Xiaobo Sun, Wei Qiu |
Journal | Neuroimmunomodulation
(Neuroimmunomodulation)
Vol. 28
Issue 3
Pg. 187-192
( 2021)
ISSN: 1423-0216 [Electronic] Switzerland |
PMID | 34237754
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 S. Karger AG, Basel. |
Chemical References |
- Autoantibodies
- Glial Fibrillary Acidic Protein
- Staphylococcal Protein A
- Methylprednisolone
|
Topics |
- Astrocytes
- Autoantibodies
- Glial Fibrillary Acidic Protein
- Humans
- Male
- Methylprednisolone
(therapeutic use)
- Middle Aged
- Retrospective Studies
- Staphylococcal Protein A
|